Key Takeaways:
Oculis Holding AG (Nasdaq: OCS) has completed the final patient visit in its Phase 3 DIAMOND program for OCS-01 eye drops.
The announcement was made in a company press release on April 20, 2026.
The Phase 3 DIAMOND (Diabetic Macular Edema) program is a two-stage trial evaluating the efficacy and safety of OCS-01 in treating DME. OCS-01 is a novel, high-concentration topical formulation of dexamethasone.
This milestone moves OCS-01 one step closer to becoming the first topical treatment for DME, a market currently dominated by invasive therapies. Investors will be closely watching for the topline results in June 2026.
Diabetic Macular Edema is a complication of diabetes caused by fluid accumulation in the macula, the central part of the retina. It affects approximately 37 million people worldwide and is a leading cause of vision loss among the diabetic population. Current treatments for DME, such as anti-VEGF injections and steroid implants, are invasive and can be burdensome for patients.
OCS-01 is a proprietary, high-concentration formulation of dexamethasone designed to reach the back of the eye with a simple eye drop. A successful outcome for OCS-01 would represent a significant breakthrough in the treatment of DME, offering a non-invasive alternative to the current standard of care.
The completion of the Phase 3 trial significantly de-risks the clinical development of OCS-01. A positive data readout in June could lead to a substantial increase in Oculis's stock price and open up a significant new revenue stream for the company.
This article is for informational purposes only and does not constitute investment advice.
